Effects of BDNF polymorphisms on antidepressant action.
Evidence suggests that the down-regulation of the signaling pathway involving brain-derived neurotrophic factor (BDNF), a molecular element known to regulate neuronal plasticity and survival, plays an important role in the pathogenesis of major depression. The restoration of BDNF activity induced by antidepressant treatment has been implicated in the antidepressant therapeutic mechanism. Because there is variability among patients with major depressive disorder in terms of response to antidepressant treatment and since genetic factors may contribute to this inter-individual variability in antidepressant response, pharmacogenetic studies have tested the associations between genetic polymorphisms in candidate genes related to antidepressant therapeutic action. In human BDNF gene, there is a common functional polymorphism (Val66Met) in the pro-region of BDNF, which affects the intracellular trafficking of proBDNF. Because of the potentially important role of BDNF in the antidepressant mechanism, many pharmacogenetic studies have tested the association between this polymorphism and the antidepressant therapeutic response, but they have produced inconsistent results. A recent meta-analysis of eight studies, which included data from 1,115 subjects, suggested that the Val/Met carriers have increased antidepressant response in comparison to Val/Val homozygotes, particularly in the Asian population. The positive molecular heterosis effect (subjects heterozygous for a specific genetic polymorphism show a significantly greater effect) is compatible with animal studies showing that, although BDNF exerts an antidepressant effect, too much BDNF may have a detrimental effect on mood. Several recommendations are proposed for future antidepressant pharmacogenetic studies of BDNF, including the consideration of multiple polymorphisms and a haplotype approach, gene-gene interaction, a single antidepressant regimen, controlling for age and gender interactions, and pharmacogenetic effects on specific depressive symptom-clusters.
Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
Shih-Jen
SJ
Tsai
Chen-Jee
CJ
Hong
Ying-Jay
YJ
Liou
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13208-13
16924103
Am J Med Genet B Neuropsychiatr Genet. 2008 Jul 5;147B(5):594-9
18081157
Biol Psychiatry. 2009 Sep 1;66(5):477-85
19500776
J Psychopharmacol. 2010 Dec;24(12):1755-63
19493959
Biol Psychiatry. 2003 Oct 1;54(7):703-9
14512210
Med Hypotheses. 2006;66(2):319-22
16309851
J Clin Psychiatry. 2000;61 Suppl 6:4-6
10775017
Biol Psychiatry. 2001 Aug 15;50(4):260-5
11522260
Mol Psychiatry. 2002;7(6):579-93
12140781
Neurosci Lett. 2008 May 30;437(2):130-4
18450378
Eur Neuropsychopharmacol. 2010 Aug;20(8):535-44
20167454
Neuropharmacology. 2003 Aug;45(2):251-9
12842131
Mol Psychiatry. 2010 Mar;15(3):260-71
18852698
J Neurosci. 1998 Nov 1;18(21):8700-11
9786977
Pharmacogenomics J. 2011 Apr;11(2):146-54
20195291
Neuropsychobiology. 2010;61(2):71-8
20016225
Mol Psychiatry. 2010 May;15(5):473-500
18982004
Neuropsychopharmacology. 2009 Nov;34(12):2517-28
19641488
Biol Psychiatry. 2003 Jul 1;54(1):70-5
12842310
Neuropsychopharmacology. 2000 Aug;23(2):205-15
10882847
Neurobiol Dis. 2009 Mar;33(3):358-68
19095063
Med Hypotheses. 2004;62(1):19-22
14728999
Brain Res. 2006 Nov 6;1118(1):176-82
16979146
Am J Hum Genet. 2002 Sep;71(3):651-5
12161822
Arch Gen Psychiatry. 2009 May;66(5):488-97
19414708
Psychiatry Res. 2002 Mar 15;109(2):143-8
11927139
Neuron. 1990 Oct;5(4):501-9
1688327
Med Hypotheses. 2005;65(5):942-6
16002234
EMBO J. 1990 Aug;9(8):2459-64
2369898
J Neurosci. 1995 Nov;15(11):7539-47
7472505
Biol Psychiatry. 2006 Apr 15;59(8):673-80
16458264
Biol Psychiatry. 2008 Apr 1;63(7):642-9
17981266
Pharmacogenet Genomics. 2007 Mar;17(3):207-15
17460549
Science. 2006 Oct 6;314(5796):140-3
17023662
Int J Neuropsychopharmacol. 2010 Feb;13(1):93-101
19236730
Ann Neurol. 1994;35 Suppl:S9-12
8185304
J Clin Psychiatry. 2002 Sep;63(9):826-37
12363125
Bipolar Disord. 2007 Aug;9(5):521-5
17680923
Biol Psychiatry. 2009 Oct 1;66(7):674-80
19589503
Am J Med Genet B Neuropsychiatr Genet. 2007 Sep 5;144B(6):820-3
17373693
Neurobiol Aging. 2006 Dec;27(12):1834-7
16343697
Pharmacogenomics J. 2008 Apr;8(2):101-12
17505499
Mol Psychiatry. 2002;7(2):136-7
11840305
Mol Psychiatry. 2007 Mar;12(3):247-57
17146470
Pharmacogenomics J. 2008 Dec;8(6):384-90
18195729
Am J Geriatr Psychiatry. 2007 Oct;15(10):850-7
17911362
J Psychopharmacol. 2007 Aug;21(6):650-6
17092970
Annu Rev Neurosci. 1999;22:295-318
10202541
Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):235-42
19504537
Eur Arch Psychiatry Clin Neurosci. 2007 Feb;257(1):31-5
17036259
Acta Psychiatr Scand Suppl. 1994;377:11-5
7914394
Pharmacol Biochem Behav. 1997 Jan;56(1):131-7
8981620
Arch Gen Psychiatry. 1997 Jul;54(7):597-606
9236543
Biol Psychiatry. 2003 Nov 15;54(10):994-1005
14625141
Cell. 2003 Jan 24;112(2):257-69
12553913
Am J Med Genet B Neuropsychiatr Genet. 2003 Nov 15;123B(1):19-22
14582140
Behav Brain Res. 2009 Sep 14;202(2):245-51
19463708
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15239-44
10611369
Pharmacogenet Genomics. 2008 Oct;18(10):869-75
18794724
Pharmacogenomics. 2008 Sep;9(9):1353-8
18781861
Neuropsychobiology. 2003;48(4):186-9
14673216
JAMA. 2003 Jun 18;289(23):3095-105
12813115
Rejuvenation Res. 2009 Dec;12(6):387-93
20014955